The decision-making includes an understanding that breast conservation is equivalent to MRM in terms of local control and survival [8, 9] or better. [9] We observed that most patients made the decision at the first attempt and they could understand the content of the video well. Two patients had changed their decision to MRM after interference from the husband or family member. One patient viewed the video 2 of times and opted for BCS with SLNB.
All patients wanted to see such videos for different aspects of treatment in future.
We found that both literate and illiterate patients found the video useful and simple for decision-making. Most of the patients had fewer queries postoperatively and some patients have recommended this video to other breast cancer patients. In our setup, the outpatient and chemotherapy bay have opportunities for social interaction and patients can discuss different aspects of their treatment with other patients. For the surgeon and the residents as it saved time in the busy OPD with Quality content and thereby making it a boon. We would like to reiterate the fact that surgeon's history taking examination and counseling is the main factor in establishing the patient-surgeon relationships. However, certain aspects of treatment which are complex and need proper understanding can be best understood using these animation videos.
We feel that the surgeon's outlook and counseling is the most important decisive factor in the decision-making of breast conservation or mastectomy. A study from Australia on breast conservation eligible patients opting for mastectomy revealed surgeons advise as the most important factor among various factors such as body image,fear of others reaction to the body, fear of cancer recurrence, advise form other patients, advise from breast nurse and fear of further operation. [10] We in our study observed that patients and relatives were satisfied with the animation and its content and quality. However, the animation did not address breast oncoplastic procedures which are a part of some BCS. Many women were happy to view this video and the decision-making according to them was straight forward after viewing this video.
Conclusion
We conclude that animation video can provide an unbiased view on decision-making for the surgical treatment of early breast cancer patients.
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Letter to the Editor
Intravenous potassium chloride (20 meq/h) and oral syrup Potassium chloride 20 mL every four hourly (200 mL contain 40 meq potassium) were started and continued for 3 days. Patient's power in upper limbs started improving by the 2 nd day, and the power in lower limbs started improving by the 3 rd day. On the fourth day, his serum potassium was 3.2 mEq/L. Power improved to Grade 4 in both upper limbs as well as lower limbs and he was able to walk.
Abiraterone was restarted after recovery in 250 mg daily dose, increasing to 1000 mg/day. He has been tolerating the dose since the past 6 months.
Abiraterone with prednisolone is a standard of care in metastatic prostate cancer.
In April 2011, the Food and Drug Administration approved androgen synthesis inhibitor abiraterone acetate in combination with low-dose prednisone, for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. [1, 2] There are two large randomized clinical trials which demonstrated that the combination of abiraterone plus androgen deprivation therapy significantly prolongs overall survival in patients with castration-sensitive prostate cancer. [3, 4] The most common adverse reactions with Abiraterone are fatigue, backache or joint discomfort, peripheral edema, diarrhea, nausea, constipation, hypokalemia manifesting as torsades des pointes, atrial fibrillation, hypertension, glucocorticoid deficiency, increased alanine aminotransferase, aspartate aminotransferase, and cardiac disorder. [1] Abiraterone-induced severe hypokalemia is very rare and can occur without diarrhea. Severe hypokalemia leading to quadriplegia is extremely unusual. Abiraterone causes Grade 3 and Grade 4 hypokalemia (10% and 1%, respectively). [3] We believe that this is primarily due to abiraterone as he had mild diarrhea (one or two motion only), that too 3-4 days before developing quadriplegia. He had stopped the medication during diarrhea and restarted it after 3-4 days when he presented to us with quadriplegia.
Adverse effects of abiraterone such as hypertension, hypokalemia, fluid retention, and edema occur due to increase in mineralocorticoid activity resulting from CYP17 inhibition. It should be used cautiously in cases of cardiovascular disease, uncorrected hypokalemia, adrenocorticoid insufficiency, mineralocorticoid excess, and hepatic disease.
We also believe that more frequent monitoring of serum potassium is required in certain cases such as frail patients and those with diarrhea or vomiting.
To the best of our knowledge, this is the first case of abiraterone-induced severe hypokalemia leading to quadriplegia reported in literature.
Correction of hypokalemia and control of hypertension before and during treatment is mandatory. Monitoring of blood pressure and serum potassium should be done at least once a month. Rather a broad recommendation of monthly monitoring of serum potassium, we believe more aggressive monitoring of serum potassium in the selected set of patients is required.
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